Showing 3481-3490 of 4177 results for "".
- FDA Approves First Treatment for Rare Form of Skin Cancerhttps://practicaldermatology.com/news/fda-approves-first-treatment-for-rare-form-of-skin-cancer/2458236/The FDA granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a r
- Positive Results Announced from SebuDerm Gel Study in Treatment of Seborrheic Dermatitishttps://practicaldermatology.com/news/positive-results-announced-from-sebuderm-gel-study-in-treatment-of-seborrheic-dermatitis/2458237/The results of a clinical study evaluating the impact of Sonoma Pharmaceuticals, Inc.'s SebuDerm (topical hypochlorous acid) gel in the treatment of mild to moderate facial and scalp seborrheic dermatitis were presented at the 13th Annual Maui Dermatology Conference in Maui, HI.
- AAD Throws Some Shade At 26 Schools With 2017 Shade Structure Grantshttps://practicaldermatology.com/news/aad-throws-some-shade-at-26-schools-with-2017-shade-structure-grants/2458245/The American Academy of Dermatology (AAD) awarded shade structure grants to 26 schools and non-profit organizations across the country. Since its launch in 2000, the AAD’s Shade Structure Grant Program has awarded 350 shade structure grants, which pr
- Serlopitant May Stop the Itch of Prurigo Nodularishttps://practicaldermatology.com/news/serlopitant-may-stop-the-itch-of-prurigo-nodularis/2458252/Menlo Therapeutics Inc.’s Serlopitant performed well in phase 2 trial (TCP-102) evaluating it as a treatment of pruritus associated with prurigo nodularis, successfully meeting its primary efficacy endpoint and key sec
- New Biomarker May Help Guide Metastatic Melanoma Treatment Decisionshttps://practicaldermatology.com/news/new-biomarker-may-guide-metastatic-melanoma-treatment-decisions/2458253/Measuring levels of Bim—a protein made by cancer-fighting T cells—via a simple blood draw can help doctors predict which metastatic melanoma patients would benefit from anti-PD-1 checkpoint blockade. Such personalized medicine can help eliminate some of the trial and error ass
- New Research Closes In On Personalized AD Therapyhttps://practicaldermatology.com/news/new-research-closes-in-on-personalized-therapy-for-ad/2458254/New research on skin lipids may pave the way toward personalized therapies for atopic dermatitis. Researchers can now identify the precise lipids found in the skin of people who have atopic dermatitis, and compare them to people with healthy skin. Here’s how: A type of tape can pull
- Rare Disease Breakthrough? New Treatment May Reduce Blistering in EBShttps://practicaldermatology.com/news/rare-disease-breakthrough-new-treatment-may-reduce-blistering-in-ebs/2458255/In a possible breakthrough in the treatment of epidermolysis bullosa simplex (EBS), Diacerein 1% ointment reduced blistering in patients with this rare genetic connective tissue disorder. The new findings were presented in a late-breaker session at the American Academy of Dermatology Annu
- Mosquito Virus Expert Discusses a Promising New Drug For Zikahttps://practicaldermatology.com/news/mosquito-virus-expert-discusses-a-promising-new-drug-for-zika/2458257/Thomas Voss, PhD, a world-renowned leader in infectious disease research, and his team, say there are two strategies for developing a defense program against Zika infection: prevention, achieved by developing an effective vaccine and vaccination program or the development of a drug that can kill
- Galderma and Colorescience Launch Collaborationhttps://practicaldermatology.com/news/galderma-and-colorescience-launch-collaboration/2458265/Galderma will collaborate with Colorescience to expand skincare solutions to individuals who seek innovative daily skincare products that can be used in conjunction with traditional facial injectable aesthetic treatments, the companies have announced. Galderma and Color
- Galderma Moves to Differentiate Their Two New HA Fillers From The Frayhttps://practicaldermatology.com/news/galderma-moves-to-differentiate-their-two-new-ha-fillers-from-the-fray/2458262/With a growing number of hyaluronic acid (HA) fillers available and even more in the pike, Galderma is highlighting how their two newest fillers --Restylane Refyne and Restylane Defyne --stand out from the crowd. In a word: flexibility. Th